Altarex Corp.

MAb prolongs disease-free survival in optimal chemosensitive patients

Published in Oncology Business Week, May 30th, 2004

Compared with placebo, the monoclonal antibody oregovomab (OvaRex; Altarex Corp.) shows "significant clinical benefit to patients with chemosensitive, optimal ovarian cancer as a consolidation therapy," according to results of a randomized, prospective, Phase II clinical trial.

Authors from participating study sites - David Geffen School of Medicine at the University of California, Los Angeles (UCLA); University of Virginia; Texas Oncology PA in Dallas; University of Pittsburgh - and from Altarex Corp. and Unither Pharmaceuticals reported the trial data at the Society of Gynecologic Oncologists 2004 Annual Meeting on Women's Cancer. The first author on the study is...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Oncology Business Week

Source: Oncology Business Week (2004-05-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry